View Clinical Trial (Medical Research Study)
Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma
| City: |
|
Philadelphia |
| State: |
|
Pennsylvania |
| Zip Code: |
|
19107 |
| Conditions: |
|
Retinoblastoma |
| Purpose: |
|
Over the past 15 years, intravenous chemotherapy has become the most popular conservative
(eye-saving) method for retinoblastoma treatment because it is often effective and usually
safe. In recent years, there has been much interest in providing highly focused (focal)
chemotherapy to a diseased organ including the liver, brain, and eye. With focused
chemotherapy, the chemotherapy drugs are injected directly into the ophthalmic artery (the
artery that supplies blood to the eye). A benefit of focal chemotherapy delivery is that it
decreases the chance of toxicity to other organs such as bone marrow suppression (causing
low blood counts) and the development of other cancers in the future.
|
| Study Summary: |
|
The management of retinoblastoma includes systemic chemotherapy (carboplatin, etoposide, and
vincristine), thermotherapy, cryotherapy (freezing treatment), laser photocoagulation,
plaque radiotherapy, external beam radiotherapy, and enucleation. The treatment is tailored
to each individual case. Over the past 15 years, intravenous chemotherapy has risen as the
most popular conservative (eye-saving) method for retinoblastoma management because it is
effective and safe. In recent years, there has been keen interest in providing chemotherapy
more focally to a diseased organ including the liver, brain, and eye. The benefit of focal
chemotherapy delivery is to avoid toxicity to other organs and this toxicity includes the
risk of future cancers.
|
| Criteria: |
|
Inclusion Criteria:
- Advanced retinoblastoma in one or both eyes
- Recurrent retinoblastoma after failure of previous treatment
- No age limit (usually kids presenting with retinoblastoma present in the 1st two
decades of life)
- Judged by principal investigator to be medically and physically able to undergo the
procedure
Exclusion Criteria:
- Recurrent retinoblastoma which is treatable with other conservative measures
- Invasive retinoblastoma (retinoblastoma that has grown locally outside of the eye,
for example, into the bone around the eye)
|
| NCT ID: |
|
NCT00857519 |
| Primary Contact: |
|
Principal Investigator
Carol L Shields, MD
Oncology Service, Wills Eye Institute
Carol L Shields, MD
Phone: 215-928-3105
Email: carol.shields@shieldsoncology.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Philadelphia, Pennsylvania 19107
United States
Carol L Shields, MD
Phone: 215-928-3105
Email: carol.shields@shieldsoncology.com
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|